UnknownNot Applicable

Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer

United States20 participantsStarted 2006-07

Plain-language summary

RATIONALE: Regenecare® wound gel may help relieve pain and itching in patients who develop an acne-like rash while undergoing treatment with cetuximab or another epidermal growth factor receptor inhibitor for cancer. PURPOSE: This clinical trial is studying how well Regenecare® wound gel works in treating rash in patients receiving cetuximab or another epidermal growth factor receptor inhibitor therapy for cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosis of cancer * Starting treatment with cetuximab or other EGFR inhibitor (e.g., erlotinib hydrochloride) on another clinical trial PATIENT CHARACTERISTICS: * Not pregnant or nursing * No known history of hypersensitivity to amine-type local anesthetics or to other components of MPM Regenecare® wound gel * No other concurrent, serious skin disorders (i.e., scleroderma or psoriasis) that would interfere with assessment of EGFR inhibitor-induced rash PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No other concurrent topical facial creams or lotions

What they're measuring

Efficacy of Regenecare® wound gel, in terms of alleviating pain and itching

Trial details

NCT IDNCT00498992

SponsorIngalls Memorial Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Dermatologic Complications trials